Skip to main content

Table 2 Clinical outcomes of patients with HBV-related acute-on-chronic liver failure on tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment

From: Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B

Outcome, n (%)

TAF 25 mg

TDF 300 mg

ETV 0.5 mg

P value

(n = 10)

(n = 10)

(n = 20)

Mortality or transplantation

 Within 28 days

1 (10)

3 (30)

2 (10)

0.504

 Within 3 months

2 (20)

4 (40)

3 (15)

0.320

 Within 48 weeks

2 (20)

4 (40)

3 (15)

0.320

Liver-related complications (first 3 months)

 Ascites

7 (70)

7 (70)

13 (65)

0.945

 Spontaneous bacterial peritonitis

6 (60)

6 (60)

11 (55)

0.950

 Infection during treatment

3 (30)

4 (40)

7 (35)

0.896

 Gastrointestinal hemorrhage

0 (0)

1 (10)

1 (5)

0.591

 Hepatorenal syndrome

1 (10)

2 (20)

0 (0)

0.244

 Hepatic encephalopathy

0 (0)

2 (20)

1 (5)

0.299